Galactostasis (Milk Accumulation / Galactostasis)

Galactostasis, also known as milk stasis or milk accumulation, is a pathological condition in lactating female dogs and cats characterized by the inadequate or complete failure of milk removal from the mammary glands, leading to the accumulation of milk within the glandular tissue and ducts. This condition is typically associated with the postpartum period, but can also occur during pseudopregnancy or in cases of weaning. The accumulation of milk causes increased intramammary pressure, leading to glandular engorgement, pain, and inflammation. If left untreated, galactostasis can progress to mastitis, mammary gland necrosis, or systemic infection. The condition is a common clinical entity in small animal theriogenology, particularly in bitches and queens with large litters, inadequate nursing, or early weaning. The pathophysiology involves a disruption in the delicate balance between milk production (lactogenesis) and milk removal (milk ejection). Lactogenesis is primarily driven by prolactin, while milk ejection is mediated by oxytocin. Any factor that interferes with the suckling stimulus, such as weak or deceased neonates, maternal neglect, or mastitis, can lead to galactostasis. The condition is classified as a non-infectious inflammatory disorder initially, but secondary bacterial infection can occur, leading to septic mastitis. In severe cases, galactostasis can result in galactocele formation, abscessation, or gangrenous mastitis. Early recognition and appropriate management are crucial to prevent complications and preserve the mammary gland function for future lactation.

The primary etiological factor in galactostasis is the failure of milk removal from the mammary glands. This can be due to a variety of causes, including: 1) Inadequate suckling by neonates: This is the most common cause, often seen in large litters where some puppies or kittens are weak, have a poor suckling reflex, or are unable to compete for access to the teats. 2) Maternal factors: The dam or queen may have painful or cracked nipples, mastitis, or a poor mothering instinct, leading to avoidance of nursing. 3) Early weaning or separation of neonates: Abrupt weaning or removal of the litter before the natural weaning age can lead to milk accumulation. 4) Pseudopregnancy: In non-pregnant bitches, hormonal imbalances can cause lactation and subsequent galactostasis if milk is not removed. 5) Iatrogenic causes: Administration of medications that inhibit oxytocin release or milk ejection, such as certain tranquilizers or alpha-adrenergic agonists, can contribute. 6) Anatomical abnormalities: Congenital or acquired abnormalities of the teat or mammary gland, such as inverted nipples, can impede milk flow. 7) Systemic diseases: Conditions that cause maternal illness, such as eclampsia or metritis, can reduce nursing frequency. The underlying mechanism involves the accumulation of milk in the alveoli and ducts, leading to increased pressure, epithelial cell damage, and activation of inflammatory mediators. The release of milk components into the interstitial tissue can trigger a foreign body reaction, further exacerbating inflammation. Secondary bacterial infection, most commonly with Staphylococcus spp., Streptococcus spp., or Escherichia coli, can occur due to ascending infection through the teat canal or via hematogenous spread, leading to suppurative mastitis.

Galactostasis is a common condition in small animal practice, particularly in the postpartum period. The exact incidence is not well-documented, but it is estimated to occur in up to 10-20% of lactating bitches and queens. Certain breeds may be predisposed due to conformational factors, such as large mammary glands or small teat size. In dogs, breeds with large litters, such as Labrador Retrievers, Golden Retrievers, and Beagles, may be at higher risk due to the increased demand for milk and the potential for inadequate nursing. In cats, breeds with large litters, such as Siamese and Oriental Shorthairs, may also be predisposed. Age does not appear to be a significant risk factor, but primiparous animals may be more susceptible due to inexperience in nursing and potential anatomical immaturity of the mammary glands. Parity may play a role, as older multiparous animals may have more pendulous mammary glands, which can be more prone to trauma and milk stasis. The condition is more common in animals that have undergone cesarean section, as the neonates may be weaker and less likely to nurse effectively. Additionally, animals that have experienced dystocia or have had a prolonged labor may have neonates with reduced vitality. Environmental factors, such as poor hygiene in the whelping area, can increase the risk of secondary bacterial infection. The condition is also seen in non-pregnant animals with pseudopregnancy, particularly in bitches, where the incidence is higher in those that have been bred but failed to conceive or have been treated with progestins.

The pathophysiology of galactostasis involves a complex interplay of endocrine, cellular, and mechanical factors. During lactation, the mammary glands undergo cycles of milk synthesis and secretion, which are regulated by prolactin and local autocrine factors. Milk ejection is mediated by the neuroendocrine reflex, where suckling stimulates the release of oxytocin from the posterior pituitary, causing contraction of myoepithelial cells around the alveoli and ducts, propelling milk towards the teat. When milk removal is inadequate, the following sequence of events occurs: 1) Increased intramammary pressure: As milk accumulates, the pressure within the alveoli and ducts rises, leading to distension of the glandular tissue. This pressure can exceed the capillary perfusion pressure, leading to local ischemia and hypoxia. 2) Epithelial cell damage: The increased pressure and ischemia cause damage to the mammary epithelial cells, leading to disruption of tight junctions and leakage of milk components (e.g., casein, lactose, immunoglobulins) into the interstitial space. 3) Inflammatory response: The extravasated milk components act as irritants, triggering an acute inflammatory response characterized by vasodilation, increased vascular permeability, and recruitment of neutrophils and macrophages. This results in the clinical signs of heat, pain, redness, and swelling. 4) Activation of the coagulation cascade: The inflammatory response can activate the coagulation cascade, leading to microthrombosis and further ischemia. 5) Fibrosis and glandular involution: If the condition persists, the inflammatory process can lead to fibrosis and destruction of the glandular tissue, resulting in permanent loss of milk-producing capacity. 6) Secondary bacterial infection: The compromised glandular tissue and the presence of milk, which is an excellent culture medium, predispose to bacterial colonization. Bacteria can ascend through the teat canal or spread hematogenously, leading to suppurative mastitis. The infection can further damage the glandular tissue and lead to abscess formation or gangrene. The systemic effects of galactostasis are usually mild initially, but if mastitis develops, the release of bacterial toxins and inflammatory mediators can lead to fever, lethargy, and septicemia.

Several intrinsic and extrinsic factors predispose to galactostasis. Intrinsic factors include: 1) Primiparity: First-time mothers may have less efficient milk ejection reflexes and may be more prone to neglect their offspring. 2) Anatomical abnormalities: Inverted or hypoplastic teats can impede milk flow. 3) Large litter size: A large number of neonates can lead to competition for teats, leaving some glands unemptied. 4) Weak or ill neonates: Neonates with poor suckling reflexes due to prematurity, congenital defects, or maternal anesthesia during cesarean section may not effectively empty the glands. 5) Maternal illness: Conditions such as eclampsia, metritis, or mastitis can reduce the dam's willingness to nurse. 6) Pseudopregnancy: Hormonal imbalances can cause lactation without the presence of neonates, leading to milk accumulation. Extrinsic factors include: 1) Early weaning: Abrupt separation of the litter before the natural weaning age. 2) Inadequate nursing management: Failure to ensure that all neonates are nursing from all glands. 3) Poor hygiene: Contaminated environment can increase the risk of bacterial infection. 4) Iatrogenic: Administration of drugs that inhibit oxytocin release, such as alpha-adrenergic agonists or certain tranquilizers. 5) Stress: Environmental stress, such as loud noises or excessive human handling, can inhibit the milk ejection reflex. 6) Nutritional factors: Inadequate nutrition can affect milk production and let-down.

The clinical signs of galactostasis are primarily localized to the mammary glands, but systemic signs may be present if mastitis develops. The affected mammary glands are typically enlarged, firm, warm, and painful on palpation. The skin over the gland may be erythematous and tense. The milk may be difficult to express, and when expressed, it may appear normal or slightly thickened. The animal may show signs of discomfort, such as restlessness, panting, or reluctance to allow the neonates to nurse. In some cases, the animal may have a fever, lethargy, and decreased appetite, especially if secondary bacterial infection is present. The neonates may also show signs of inadequate milk intake, such as crying, weight loss, or failure to thrive. In severe cases, the gland may become abscessed, with the formation of a fluctuant mass that may rupture and drain purulent material. Gangrenous mastitis can occur, characterized by a dark, cold, and necrotic gland, which is a medical emergency. The clinical signs can be graded based on severity: Grade 1 (mild) – slight enlargement and firmness of one or more glands, with no systemic signs; Grade 2 (moderate) – more pronounced enlargement, pain, and erythema, with possible mild fever; Grade 3 (severe) – marked enlargement, severe pain, systemic signs such as fever, lethargy, and anorexia, and possible abscessation or necrosis.

The differential diagnoses for galactostasis include: 1) Mastitis: This is the most important differential, as it can be a sequela of galactostasis. Mastitis is characterized by the presence of systemic signs, abnormal milk (e.g., purulent, bloody, or clotted), and cytological evidence of bacteria and inflammatory cells. 2) Mammary gland neoplasia: Tumors can present as firm masses in the mammary gland, but they are usually not associated with lactation and are more common in older animals. Fine-needle aspiration and cytology can differentiate. 3) Mammary gland hyperplasia: This can occur during the estrous cycle or pregnancy, but it is usually bilateral and not associated with lactation. 4) Galactocele: A milk-filled cyst that can form as a complication of galactostasis. It presents as a fluctuant mass, and ultrasound can confirm the presence of a cystic structure. 5) Abscess: A localized collection of pus that can occur secondary to mastitis. It is fluctuant and may be associated with systemic signs. 6) Trauma: A contusion or hematoma of the mammary gland can cause swelling and pain, but there is usually a history of trauma. 7) Eclampsia (puerperal tetany): This condition is characterized by hypocalcemia and can cause restlessness, muscle tremors, and seizures, but it does not typically cause mammary gland enlargement. 8) Metritis: This is an infection of the uterus, which can cause systemic signs and vaginal discharge, but the mammary glands are usually normal. 9) Pseudopregnancy: This condition can cause lactation and mammary gland enlargement in non-pregnant animals, but it is not associated with the presence of neonates. 10) Foreign body reaction: A foreign body, such as a grass awn, can cause localized inflammation and swelling, but it is usually unilateral and may have a draining tract.

The diagnostic approach to galactostasis involves a step-by-step process: 1) History and clinical examination: Obtain a thorough history, including the number of neonates, their nursing behavior, and the duration of lactation. Perform a complete physical examination, with special attention to the mammary glands. Palpate each gland to assess size, consistency, pain, and temperature. Note any skin changes, discharge, or masses. 2) Assessment of neonates: Evaluate the neonates for signs of adequate milk intake, such as weight gain, activity, and a full stomach. 3) Milk expression and evaluation: Attempt to express milk from the affected glands. Note the color, consistency, and odor of the milk. Perform a cytological examination of the milk to look for inflammatory cells and bacteria. 4) Complete blood count (CBC) and serum biochemistry: These tests can help identify systemic inflammation or infection. Leukocytosis with a left shift may indicate mastitis. 5) Ultrasonography: This imaging modality can be used to evaluate the mammary gland parenchyma, detect abscesses or galactoceles, and guide fine-needle aspiration. 6) Fine-needle aspiration (FNA) and cytology: If a mass or abscess is suspected, FNA can be performed to obtain samples for cytological examination and culture. 7) Bacterial culture and sensitivity: If mastitis is suspected, milk or aspirate samples should be submitted for aerobic bacterial culture and antimicrobial susceptibility testing. 8) Rule out other conditions: Based on the clinical signs, consider differential diagnoses such as mastitis, neoplasia, or eclampsia. Perform additional tests as needed, such as serum calcium levels for eclampsia or biopsy for suspected neoplasia. 9) Monitor response to treatment: If galactostasis is diagnosed, initiate treatment and monitor the response. If the condition does not improve or worsens, reassess the diagnosis and consider additional diagnostic tests.

In uncomplicated galactostasis, laboratory findings are often within normal limits. However, if secondary mastitis develops, the following abnormalities may be observed: 1) Complete blood count (CBC): Leukocytosis with a left shift (increased band neutrophils) is common in bacterial mastitis. Toxic changes in neutrophils may be seen in severe cases. Anemia may be present if there is significant blood loss or chronic inflammation. 2) Serum biochemistry: Acute phase proteins, such as C-reactive protein, may be elevated. Liver enzymes (ALT, AST) may be mildly elevated due to systemic inflammation. In cases of eclampsia, hypocalcemia (total calcium < 8.0 mg/dL) may be present. 3) Milk cytology: The milk may contain increased numbers of neutrophils, macrophages, and bacteria. Intracellular bacteria may be seen in cases of septic mastitis. 4) Milk culture: Aerobic bacterial culture can identify the causative organism, most commonly Staphylococcus spp., Streptococcus spp., and Escherichia coli. 5) Vaginal cytology: This is not typically performed in galactostasis, but may be useful to rule out metritis. 6) Hormonal assays: Serum progesterone and prolactin levels may be measured in cases of pseudopregnancy, but are not routinely indicated in galactostasis. 7) Histopathology: If a biopsy is performed, it may show dilated alveoli filled with eosinophilic proteinaceous material (milk), flattening of the epithelial cells, and infiltration of inflammatory cells.

Imaging modalities are useful in the evaluation of galactostasis and its complications. 1) Abdominal ultrasonography: This is the primary imaging modality for evaluating the mammary glands. In galactostasis, the affected glands may appear enlarged with increased echogenicity of the parenchyma due to edema and inflammation. The ducts may be dilated and filled with anechoic or hypoechoic fluid. Ultrasonography can also detect the presence of abscesses (well-defined, hypoechoic to anechoic cavities with thick walls) or galactoceles (simple cysts filled with anechoic fluid). Color Doppler may show increased blood flow in the inflamed gland. 2) Radiography: Plain radiography is of limited value in the evaluation of the mammary glands, but it may be useful to rule out other conditions such as foreign bodies or neoplasia. 3) Computed tomography (CT) and magnetic resonance imaging (MRI): These advanced imaging modalities are rarely needed but can provide detailed anatomical information in complex cases, such as suspected neoplasia or deep abscesses. 4) Vaginoscopy: This is not directly relevant to galactostasis but may be performed to rule out vaginal or uterine pathology if there is concurrent vaginal discharge.

Cytological and histopathological examination is essential for confirming the diagnosis and ruling out other conditions. 1) Fine-needle aspiration (FNA) of the mammary gland: In galactostasis, FNA may yield milk-like fluid with few cells. If mastitis is present, the aspirate may contain numerous neutrophils, macrophages, and bacteria. If a neoplastic process is suspected, the aspirate may contain epithelial cells with criteria of malignancy. 2) Milk cytology: A smear of milk can be stained with Diff-Quik or Gram stain. In normal milk, there are few cells, mainly macrophages and occasional neutrophils. In galactostasis, there may be an increased number of neutrophils, but no bacteria. In mastitis, there is a marked increase in neutrophils, often with intracellular bacteria. 3) Histopathology: If a biopsy is performed, the histopathological features of galactostasis include dilated alveoli and ducts filled with eosinophilic, proteinaceous material (milk), flattening of the alveolar epithelium, and variable degrees of interstitial edema and inflammation. In chronic cases, there may be fibrosis and atrophy of the glandular tissue. If mastitis is present, there is a marked infiltration of neutrophils, and in severe cases, areas of necrosis and abscess formation. Special stains, such as Gram stain, can help identify bacteria. Immunohistochemistry may be used to differentiate between inflammatory and neoplastic conditions.

The treatment of galactostasis aims to relieve milk accumulation, reduce inflammation, and prevent or treat secondary infection. The specific approach depends on the severity of the condition and the presence of complications. 1) Conservative management: For mild cases, the primary goal is to encourage milk removal. This can be achieved by ensuring that the neonates are nursing effectively. If the neonates are weak or unable to nurse, they may need to be supplemented with milk replacer. Frequent nursing or manual milk expression can help relieve the pressure. Warm compresses applied to the affected glands for 10-15 minutes before nursing can stimulate milk let-down. Gentle massage of the glands can also help. 2) Pharmacological therapy: a) Oxytocin: Oxytocin can be administered to promote milk ejection. The dose is 0.5-2 IU per animal (or 0.1-0.2 IU/kg) subcutaneously or intramuscularly, given 10-15 minutes before nursing or milking. This can be repeated every 4-6 hours as needed. b) Non-steroidal anti-inflammatory drugs (NSAIDs): To reduce pain and inflammation, NSAIDs such as carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h) can be used. c) Antibiotics: If secondary bacterial infection is suspected or confirmed, antibiotics should be administered. The choice of antibiotic should be based on culture and sensitivity results. Commonly used antibiotics include amoxicillin-clavulanate (12.5-25 mg/kg PO q8-12h), cephalexin (22 mg/kg PO q8-12h), or enrofloxacin (5-10 mg/kg PO q24h). It is important to consider the safety of the antibiotic in lactating animals, as some drugs may be excreted in milk and affect the neonates. d) Cabergoline: In cases of pseudopregnancy or to reduce prolactin levels, cabergoline (5 mcg/kg PO q24h for 5-7 days) can be used to decrease milk production. e) Diuretics: In severe cases of engorgement, diuretics such as furosemide (1-2 mg/kg IV or PO q8-12h) may be used to reduce edema, but they should be used with caution due to the risk of dehydration. 3) Surgical intervention: In cases of abscessation or gangrenous mastitis, surgical drainage or mastectomy may be necessary. Abscesses should be lanced, drained, and flushed with sterile saline. Gangrenous glands should be surgically removed to prevent systemic spread of infection. 4) Supportive care: Ensure adequate hydration and nutrition. In cases of systemic illness, intravenous fluids may be required. If the dam is unable to nurse the neonates, they should be hand-reared or placed with a foster mother. 5) Management of neonates: If the neonates are not nursing effectively, they may need to be supplemented with a commercial milk replacer. It is important to monitor their weight gain and overall health.

The prognosis for galactostasis is generally good if the condition is recognized and treated early. In uncomplicated cases, the condition resolves within a few days with appropriate management. The affected mammary glands usually return to normal function, and the animal can continue to lactate normally. However, if secondary mastitis develops, the prognosis is more guarded. Mastitis can lead to permanent damage to the mammary gland, resulting in reduced milk production or loss of the gland. In severe cases, such as gangrenous mastitis, the prognosis is poor, and the animal may require surgical removal of the affected gland. The overall prognosis also depends on the underlying cause. If galactostasis is due to inadequate nursing, ensuring proper nursing can lead to a full recovery. If it is due to pseudopregnancy, the condition may resolve with hormonal therapy. The prognosis for future fertility is generally unaffected, as galactostasis does not directly affect the reproductive tract. However, if the condition is recurrent, it may indicate an underlying anatomical or hormonal abnormality that could affect future lactation. Negative prognostic indicators include the presence of systemic signs, abscessation, gangrenous mastitis, and delayed treatment.

Follow-up care is essential to ensure complete resolution of galactostasis and to monitor for complications. The following schedule is recommended: 1) Daily monitoring: During the acute phase, the animal should be monitored daily for changes in the mammary glands, including size, pain, and discharge. The neonates should be weighed daily to ensure adequate milk intake. 2) Recheck in 3-5 days: If the animal is on antibiotics or anti-inflammatory medications, a recheck examination should be performed in 3-5 days to assess the response to treatment. The milk should be re-evaluated cytologically if mastitis was present. 3) Serial ultrasonography: If an abscess or galactocele was identified, follow-up ultrasound examinations may be performed every 1-2 weeks until resolution. 4) Hormonal monitoring: If cabergoline or other hormonal therapy is used, the animal should be monitored for side effects and the effectiveness of the treatment. 5) Breeding management: If the animal is intended for future breeding, it is important to ensure that the mammary glands have fully recovered before the next pregnancy. A breeding soundness examination may be recommended. 6) Long-term follow-up: In cases of recurrent galactostasis or mastitis, a thorough investigation into the underlying cause is warranted. This may include hormonal assays, imaging, and genetic testing for hereditary conditions.

Clinical pearls: 1) Always assess the neonates' nursing behavior and weight gain, as inadequate nursing is the most common cause of galactostasis. 2) Use oxytocin judiciously to promote milk let-down, but be aware that it may cause uterine contractions and should be used with caution in the immediate postpartum period. 3) Warm compresses and gentle massage before nursing can significantly improve milk flow. 4) If mastitis is suspected, perform a Gram stain on the milk to guide initial antibiotic therapy. 5) In cases of severe engorgement, consider using a breast pump designed for small animals to relieve pressure. 6) Monitor the dam for signs of eclampsia, as hypocalcemia can occur concurrently with galactostasis. Pitfalls: 1) Do not use diuretics as a first-line treatment, as they can cause dehydration and electrolyte imbalances. 2) Avoid the use of NSAIDs in animals with renal or hepatic disease, and use them with caution in lactating animals as they may be excreted in milk. 3) Do not administer oxytocin in cases of uterine obstruction or if there is a risk of uterine rupture. 4) Do not neglect the neonates; they may require supplemental feeding if the dam is unable to nurse. 5) Do not delay surgical intervention in cases of abscessation or gangrenous mastitis, as this can lead to systemic sepsis. 6) Do not assume that all mammary gland swellings are galactostasis; always consider neoplasia, especially in older animals.

The following drug protocols are based on Plumb's Veterinary Drug Handbook and current theriogenology guidelines. 1) Oxytocin: Dose: 0.5-2 IU per dog or cat, or 0.1-0.2 IU/kg, administered subcutaneously (SC) or intramuscularly (IM) 10-15 minutes before nursing or milking. May be repeated every 4-6 hours as needed. 2) Cabergoline: Dose: 5 mcg/kg orally (PO) once daily for 5-7 days. Used to reduce prolactin levels and decrease milk production in cases of pseudopregnancy or to facilitate weaning. 3) Carprofen: Dose: 2.2 mg/kg PO every 12 hours (q12h) for up to 7 days. Use with caution in lactating animals. 4) Meloxicam: Dose: 0.1 mg/kg PO once daily (q24h) for up to 5 days. Contraindicated in animals with renal disease. 5) Amoxicillin-clavulanate: Dose: 12.5-25 mg/kg PO every 8-12 hours (q8-12h). Safe for use in lactating animals, but may cause gastrointestinal upset. 6) Cephalexin: Dose: 22 mg/kg PO every 8-12 hours (q8-12h). 7) Enrofloxacin: Dose: 5-10 mg/kg PO once daily (q24h). Use with caution in young animals due to potential cartilage damage. 8) Furosemide: Dose: 1-2 mg/kg IV or PO every 8-12 hours (q8-12h). Use only in severe cases of edema, with careful monitoring of hydration status. 9) Calcium gluconate: If hypocalcemia is present, administer 10% calcium gluconate at a dose of 0.5-1.5 mL/kg IV slowly over 10-20 minutes, with cardiac monitoring. 10) Antibiotic selection should be based on culture and sensitivity. In cases of suspected gram-positive infection, a first-generation cephalosporin or amoxicillin-clavulanate is appropriate. For gram-negative infections, enrofloxacin or amikacin may be used, but amikacin should be used with caution due to nephrotoxicity.

The literature on galactostasis in small animals is limited, but several key studies and reviews provide evidence-based guidance. 1) A study by Johnston et al. (2001) in 'Canine and Feline Theriogenology' highlights the importance of early recognition and management of galactostasis to prevent mastitis. They recommend frequent nursing and manual milk expression as first-line therapy. 2) A review by Noakes et al. (2019) in 'Veterinary Reproduction and Obstetrics' discusses the pathophysiology of milk stasis and the role of oxytocin in milk ejection. They emphasize the need to address the underlying cause, such as weak neonates or maternal neglect. 3) A clinical trial by England and von Heimendahl (2010) in the 'BSAVA Manual of Small Animal Reproduction' evaluated the use of cabergoline in the management of pseudopregnancy and galactostasis. They found that cabergoline effectively reduced milk production and resolved clinical signs within 5-7 days. 4) A retrospective study by Smith et al. (2015) in the 'Journal of Small Animal Practice' examined the outcomes of mastitis in bitches. They found that early treatment with antibiotics and anti-inflammatory drugs improved the prognosis, but cases with gangrenous mastitis had a poor outcome. 5) The American College of Theriogenologists (ACT) and the European College of Animal Reproduction (ECAR) have published consensus guidelines on the management of postpartum disorders, which include recommendations for the treatment of galactostasis. These guidelines emphasize the importance of supportive care, including warm compresses, gentle massage, and ensuring adequate nursing. 6) A meta-analysis by Jones et al. (2020) in 'Veterinary Therapeutics' evaluated the efficacy of various treatments for mastitis in dogs and cats. They concluded that systemic antibiotics, combined with local therapy, were effective in most cases, but the choice of antibiotic should be based on culture and sensitivity. Overall, the evidence supports a conservative approach to galactostasis, with the use of pharmacological agents as needed to manage pain, inflammation, and infection.